Tag Archive for: CRS

Poolbeg Pharma plc – First Patient Dosed in the POLB 001 TOPICAL Clinical Trial

/in

Interim data remains on track for summer 2026 and partnering discussions continue to advance with multiple companies Highlights ·    First patient dosed in the POLB 001 TOPICAL clinical trial ·    Second site, University College London Hospital, activated with patient recruitment underway ·    Additional clinical sites expected to open imminently, supporting continued patient recruitment 13 July 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or […]

Read more

Poolbeg Pharma plc – Decision to grant European Patent received for POLB 001 in cancer immunotherapy-induced CRS

/in

Major milestone will provide IP protection in key European markets, strengthening global patent portfolio 16 June 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received formal notification of the decision to grant for its POLB 001 cancer immunotherapy-induced […]

Read more

Poolbeg Pharma plc – Two posters with POLB 001 preclinical data presented at the European Hematology Association Congress

/in

Posters highlight POLB 001’s potential in CRS prevention and ability to enhance AML treatment in elderly patients, potentially expanding into a new indication  ·    First poster shows that POLB 001 decreased key CRS-associated cytokines and did not impair bispecific antibody-induced tumour cell death in a series of preclinical investigations ·    Second poster demonstrates the potential for POLB […]

Read more

Poolbeg Pharma announces successful site activation for POLB 001 TOPICAL clinical trial

/in

Major operational milestone achieved with interim data on track for summer 2026 11 June 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the first site activation for the first-in-patient POLB 001 TOPICAL* clinical trial has occurred. This follows the successful completion of […]

Read more

Poolbeg Pharma plc – pre-IND meeting with the FDA for POLB 001

/in

FDA feedback supports Poolbeg’s proposed development pathway for POLB 001, providing further clarity for ongoing partnering discussions 26 May 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the positive outcome of a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug […]

Read more
© Optimum Strategic Communications.